R. Skells

Combined point of care SARS-CoV-2 nucleic acid and antibody testing in suspected moderate to severe COVID-19 disease

Steven F. Baker, Kenneth G. C. Smith, J. Briggs, 2020 .

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

D. Tuveson, J. Bridgewater, D. Jodrell, 2020, British Journal of Cancer.

Brief Report Combined point of care SARS-CoV-2 nucleic acid and antibody testing in suspected moderate to severe COVID-19 disease.

Steven F. Baker, Nikos, Myra, 2020 .

Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant

Steven F. Baker, Kenneth G. C. Smith, N. Walker, 2020, Cell Reports Medicine.

Point of Care Nucleic Acid Testing for SARS-CoV-2 in Hospitalized Patients: A Clinical Validation Trial and Implementation Study

Kenneth G. C. Smith, G. Dougan, M. Weekes, 2020, Cell Reports Medicine.

Combined point of care nucleic acid and antibody testing for SARS-CoV-2: a prospective cohort study in suspected moderate to severe COVID-19 disease.

S. Baker, J. Briggs, A. Ritchie, 2020, medRxiv.

The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer – a study protocol

J. Wason, A. Matakidou, E. Sala, 2021, BMC Cancer.